CRSP|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'25 | $-1.18 | - | - |
| Q3'25 | $-1.29 | $-1.17 | +9.2% |
| Q2'25 | $-1.40 | $-1.29 | +7.8% |
| Q1'25 | $-1.28 | $-1.58 | -23.8% |
| Q4'24 | $-1.19 | $-0.44 | +62.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'25 | $6M | - | - |
| Q3'25 | - | $889,000 | - |
| Q2'25 | - | $892,000 | - |
| Q1'25 | - | $865,000 | - |
| Q4'24 | - | $36M | - |
Market Data
CRSP Stock Snapshot
CRSP is currently trading at $50.76, giving CRISPR Therapeutics AG a market cap of 4.86B. Today's range spans $50.52–$51.31, with shares opening at $50.64 and moving up $0.40 (0.8%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 60/100.
Over the past year CRSP has traded between $35.38 and $78.48 - the current price is +43.5% off the 52-week low and -35.3% from the high.
Mean-reversion potential exists for CRSP - but it needs a catalyst. 32/100 (SELL), bullish sentiment (60/100), price $50.76 (in the lower half of its 52-week range in $35.38–$78.48). At 4.86B in Healthcare market cap, small-cap stocks in bearish phases don't typically recover on technicals alone - they need a news event, earnings surprise, or sector catalyst to shift the momentum. Without one, the SELL setup tends to persist longer than fundamental analysis would suggest.
Small-cap Healthcare names with SELL technicals (32/100) and bullish sentiment (60/100) like CRSP tend to experience sentiment-driven re-ratings more sharply in both directions. At $50.76 (in the lower half of its 52-week range in $35.38–$78.48), the current setup suggests a stock that needs a material positive catalyst — not incremental improvement — to reverse the technical and sentiment readings that now define the 4.86B market cap trajectory.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).